HC Surgical Specialists Limited (1B1) Fair Value & Analysis
Healthcare · SG · Market cap 57.5M SGD
Fair value as of: Jul 3, 2026
From 25 valuation models · updated today
Share price −1.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.2874 SGD – 0.3900 SGD · fair‑value band 0.4300 SGD – 1.01 SGD · the 0.3750 SGD price screens below the 0.6100 SGD fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
HC Surgical Specialists Limited (1B1) currently trades at 0.3750 SGD, while our model-based Fair Value estimate is 0.6100 SGD — implying the stock looks roughly 62.7% undervalued today. We read business quality at 75/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, HC Surgical Specialists Limited generated revenue of 19.1M SGD at a net margin of 47.2%. Revenue declined 1.7% year over year. It earns a return on equity of 46.1%. The stock trades on a trailing P/E of 6.3. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. The company provides endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on colorectal procedures in a network of clinics. It also offers treatment services for other conditions, such as haemorrhoids, anal fissure, hernia, anal abscess, cholecystitis, anal fistula, appendicitis, colorectal cancer, lipomas, cysts, and gastric cancer, vein laser vascular, laparoscopy, and other general and specialized medical services. In addition, the company provides orthopedic services comprising joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, wounds/lumps, tenosynovitis, tunnel syndrome, bumps, joint replacement, arthroscopic surgery, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, fractures, and orthobiologic injections. Further, it provides …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
HC Surgical Specialists Limited reported revenue of 19.1M SGD in FY2025 versus 23.4M SGD in FY2021, a compound −4.9%/yr. Reported net income was 8.4M SGD in FY2025, compounding +1.3%/yr from FY2021.
Is 1B1 fairly valued? → Check now
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $482.04 | $202.02 | -58% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $61.53 | $15.70 | -74% |
| Agilent Technologies, Inc A | $126.67 | $63.09 | -50% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is HC Surgical Specialists Limited (1B1) undervalued?
What is the fair value of 1B1?
What is the quality score of 1B1?
What is the revenue of HC Surgical Specialists Limited (1B1)?
What is the net profit margin of 1B1?
Does HC Surgical Specialists Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.